2025年4月10日,FDA 宣布计划逐步取消单克隆抗体和其他药物的动物实验要求。消息一出,美国传统的临床前CRO公司查尔斯河股价下跌28.13%。而在A股,以动物安评业务为主的昭衍新药开盘直接跌停,港股最低跌逾18%;做老鼠的药康生物盘中最低跌下8个多点。与之相对应的,美股AI医药开发概念股(如Certara、Schrodinger等)迎来小幅上涨,国内如泓博医药等有AI制药概念的公司在盘中也有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.